BridgeMD
New treatment option for Metabolic Syndrome X
Official title Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients
ClinicalTrials.gov ID: NCT06661655
What this study is testing
- What it's testing
- The objective of the study is to evaluate an ultraportable ultrasound device, Hepatoscope, for the non-invasive assessment of hepatic steatosis in patients with metabolic-dysfunction associated liver diseases (MASLD), by comparing its measurements with current diagnostic modalities, such as MRI-PDFF.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Adult patient below 80 yo
- Patients with MASLD/MASH recruited in treatment trials requiring MRI PDFF +/- MRE per treatment protocol, OR
- Patients with MASLD/MASH recruited in prospective cohorts requiring MRI PDFF +/- MRE per treatment protocol, OR
- Patients referred to MRI-PDFF or MRE.
- Patients who consented in written to participate in the study
You likely can't join if
- Patient in their minority (less than 18 yo) or older than 80 yo,
- Patient with active implants,
- Patient presenting with a wound where the Hepatoscope exam shall be performed (abdominal right upper quadrant)
- Patient with a history of decompensated cirrhosis,
- Patient with a history of hepatocellular carcinoma,
- Adult patient under tutorship, or unable to express informed consent,
See the full eligibility criteria
- Adult patient below 80 yo
- Patients with MASLD/MASH recruited in treatment trials requiring MRI PDFF +/- MRE per treatment protocol, OR
- Patients with MASLD/MASH recruited in prospective cohorts requiring MRI PDFF +/- MRE per treatment protocol, OR
- Patients referred to MRI-PDFF or MRE.
- Patients who consented in written to participate in the study
- Patients with ongoing social security coverage
- Patient in their minority (less than 18 yo) or older than 80 yo,
- Patient with active implants,
- Patient presenting with a wound where the Hepatoscope exam shall be performed (abdominal right upper quadrant)
- Patient with a history of decompensated cirrhosis,
- Patient with a history of hepatocellular carcinoma,
- Adult patient under tutorship, or unable to express informed consent,
- Pregnant or breast-feeding
- Person deprived from their liberty
- Patient hospitalized without providing consent or in case of an emergency
- Patient presenting with another know liver disease
The study team makes the final eligibility decision.
Where it's taking place
- Angers, France
- Clichy, France
- Paris, France
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Angers, France; Clichy, France; Paris, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.